Bristol Myers Squibb (BMY) is rated a Strong Buy due to its steady performance and undervaluation, despite recent underperformance against the market benchmark. The company offers a 4.43% forward dividend yield, more than double the sector median, with a strong history of 36 years of uninterrupted dividend payments and 18 years of consecutive dividend growth. Recent earnings have exceeded expectations, supporting a positive outlook and justifying a premium valuation. While legacy drug challenges remain, current stock pricing likely accounts for these risks, and analysts see an 11% upside potential with a $63 price target.
Bristol-Myers Squibb's growth portfolio now accounts for 54.1% of revenues and achieved a 9% year-over-year increase in the first quarter of fiscal 2026, offsetting declines in its legacy products. Strategic partnerships, acquisitions, and strong sal...
A bipartisan US congressional committee is investigating whether Merck, AbbVie, and three other major pharmaceutical companies conducted clinical trials in China that may have supported Chinese military capabilities. The inquiry focuses on due dilige...
